Literature DB >> 7520870

The antiviral effect of keishi-ni-eppi-ichi-to, a traditional Chinese herbal medicine, on influenza A2(H2N2) virus infection in mice.

M A Ball1, T Utsunomiya, K Ikemoto, M Kobayashi, R B Pollard, F Suzuki.   

Abstract

The antiviral effect of Keishi-ni-eppi-ichi-to (TJS-064), a traditional Chinese herbal medicine, was investigated in mice infected with influenza A2(H2N2) virus. When mice exposed to a 5 LD50 dose of the virus were treated orally with a 70 mg/kg dose of TJS-064 1 day before and 1 day and 4 days after the infection, 100% survived over a 25-day experimental period. At the end of this period all the control mice, treated with saline alone, had died; their mean survival time in days (MSD) was 11.2 days. When mice infected with a 10 LD50 dose of the virus were treated with TJS-064, the MSD was > 17.4 days and there was a 50% survival rate, while the control group had a MSD of 8.7 days and a 0% survival rate. No significant antiviral effect of TJS-064 was observed when the agent was administered orally to mice infected with a 100 LD50 or larger dose of influenza virus. Pulmonary consolidations, virus titers in lung tissues and HAI titers in sera of infected mice treated with TJS-064 were all significantly lower than those of infected mice treated with saline. Interferon activities were detected in sera of mice treated with the agent at a dose of 100 mg/kg orally. Since viricidal and viristatic activities of the agent against influenza virus were not demonstrated, the antiviral effects of TJS-064 may be expressed through the host's antiviral functions including interferon production.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520870     DOI: 10.1007/bf01919381

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  24 in total

1.  Effect of the interferon inducer, dextran phosphate, on influenza virus infection in mice.

Authors:  F Suzuki; N Ishida; M Suzuki; T Sato; S Suzuki
Journal:  Proc Soc Exp Biol Med       Date:  1975-09

2.  Studies on experimental influenza in mice. II. Absolute amount of virus introduced into the respiratory tract of mice by standard inhalation procedure.

Authors:  N ISHIDA; Y KOSAKA; Y SASAKI
Journal:  Tohoku J Exp Med       Date:  1959-12-25       Impact factor: 1.848

3.  Immunomodulator-induced resistance against herpes simplex virus.

Authors:  P S Morahan; E R Kern; L A Glasgow
Journal:  Proc Soc Exp Biol Med       Date:  1977-04

Review 4.  Ribavirin aerosol treatment of influenza.

Authors:  V Knight; B E Gilbert
Journal:  Infect Dis Clin North Am       Date:  1987-06       Impact factor: 5.982

5.  Influenza--United States, 1989-90 and 1990-91 seasons.

Authors:  L E Chapman; M A Tipple; L M Schmeltz; S E Good; H L Regnery; A P Kendal; H E Gary; N J Cox; L B Schonberger
Journal:  MMWR CDC Surveill Summ       Date:  1992-05-29

6.  ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

Authors:  W L DAVIES; R R GRUNERT; R F HAFF; J W MCGAHEN; E M NEUMAYER; M PAULSHOCK; J C WATTS; T R WOOD; E C HERMANN; C E HOFFMANN
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

7.  Antiherpes activity of the immunomodulator OK-432, a streptococcal preparation, in immunosuppressed mice.

Authors:  S Ikeda; K Sai; C Nishimura; A Yamamoto
Journal:  Antiviral Res       Date:  1988-12-11       Impact factor: 5.970

8.  Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza.

Authors:  D M Perrotta; M Decker; W P Glezen
Journal:  Am J Epidemiol       Date:  1985-09       Impact factor: 4.897

9.  Tilorone hydrochloride: an orally active antiviral agent.

Authors:  R E Krueger; G D Mayer
Journal:  Science       Date:  1970-09-18       Impact factor: 47.728

10.  Protective effect of biological response modifiers on murine cytomegalovirus infection.

Authors:  K Ebihara; Y Minamishima
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

View more
  1 in total

Review 1.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.